Last reviewed · How we verify
GW572016 oral tablets
At a glance
| Generic name | GW572016 oral tablets |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Molecular Profiling of Advanced Soft-tissue Sarcomas (PHASE3)
- Lapatinib Plus Trametinib in KRAS Mutant NSCLC (PHASE1, PHASE2)
- A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015) (PHASE1)
- Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2 (PHASE3)
- Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer (PHASE1, PHASE2)
- Lapatinib and Bevacizumab for Metastatic Breast Cancer (PHASE2)
- Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer (PHASE2)
- Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GW572016 oral tablets CI brief — competitive landscape report
- GW572016 oral tablets updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI